• As in humans and other

  2023-10-18

  

  As in humans and other mammalians spontaneous activity of sinoatrial pacemaker semagacestat in in the zebrafish heart crucially depends on proper HCN4 channel activity (If) and spontaneous diastolic depolarization [15,81]. Whether Na+/K+-ATPase currents regulate next to phase of myocardial repolari

• In clinical studies BA has

  2023-10-18

  

  In clinical studies, BA has been reported to promote dose-dependent LDL-C lowering effects of up to 30% as monotherapy, and up to an additional 24% when added in combination with stable statin therapy, or approximately 50% when combined with ezetimibe 109, 110, 111, 112. These effects were accompani

• TAK-632 Protein phosphorylation is an important posttranslat

  2023-10-18

  

  Protein phosphorylation is an important posttranslational mechanism for the regulation of distribution, trafficking, and function of modified proteins (Wang et al., 2014). GluA1 phosphorylation at S845 also has functional consequences (Lu and Roche, 2012). For instance, S845 phosphorylation drove tr

• br Apelin The APJ receptor ligand apelin firstly in was

  2023-10-18

  

  Apelin The APJ receptor ligand apelin firstly in 1998 was segregated from bovine stomach tissue. Human preproapelin gene located on chromosome Xq25–26.1. The apelin preproproteins consist of 77 amino risedronic acid receptor residues that are cleaved into biologically active C-terminal fragments

• br Results br Discussion br STAR Methods

  2023-10-18

  

  Results Discussion STAR★Methods Author Contributions Acknowledgments We thank Angela Walker for assistance with the manuscript; Junlin Liu, Xiangxiang Gu, Na Chen, Lu Xue, and the BV Core Facility of iHuman Institute for their support; scientists and colleagues at Amgen Inc., Zhulun W

• br Materials and methods br Results

  2023-10-17

  

  Materials and methods Results Discussion We demonstrate reduced angiogenic activity in NDRG1 overexpressing malignant glioma leading to reduced glioma growth. This antiangiogenic phenotype is paralleled by a significant upregulation of the antiangiogenic gene TNFSF15. TNFSF15 upregulation i

• Cy5 NHS ester(Et) Perhaps the first evidence of AMPKs therap

  2023-10-17

  

  Perhaps the first evidence of AMPKs therapeutic ability in DM1 came from Thomas Cooper’s laboratory where they demonstrated that insulin-independent glucose uptake was unaffected in human DM1 muscle Cy5 NHS ester(Et) treated with MET, an AMPK activator and first-line therapy for type 2 diabetes mel

• Interestingly all of the ROS

  2023-10-17

  

  Interestingly, all of the ROS1 rearrangements share a constant breakpoint in ROS1 and the fusion product contain the kinase domain resulting in aberrant ROS1 expression with constitutive kinase activity. Intrachromosomal deletions and interchromosomal translocations have demonstrated the existence o

• lgk974 The AHR potentially enhances IDO expression

  2023-10-17

  

  The AHR potentially enhances IDO-expression, possibly via crosstalk with several inflammatory signaling pathways (shown by now for IL6 and ‘signal transducer and activator of transcription’ (STAT) 3, and for NFκB, toll like receptor-pathways) [56,59,60]. IDO metabolizes Trp to kynurenines, which are

• Inhibitors of mPGES are considered

  2023-10-17

  

  Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e

• In order to improve the

  2023-10-17

  

  In order to improve the methodology of the synthesis of steroidal derivatives, our goal was the investigation of aza-Michael addition of different N-nucleophiles to 16-dehydropregnenolone in the presence of [DBU][OAc] as catalyst and reaction medium. Michael addition of electron deficient steroidal

• For the NSCLC patients with EGFR

  2023-10-17

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• The combination of Aurora kinase inhibitors with standard ch

  2023-10-17

  

  The combination of Aurora kinase inhibitors with standard chemotherapeutics or radiotherapeutics are currently in progress, such as AZD1152 plus radiotherapy in various solid cancer models. In addition, Azzariti et al. found that AZD1152-HQPA enhanced oxaliplatin and gemcitabine effectiveness in the

• Whole body loss of ACLY

  2023-10-17

  

  Whole-body loss of ACLY is early embryonic lethal, indicating that it serves non-redundant roles during development (Beigneux et al., 2004). Silencing or inhibition of ACLY suppresses the proliferation of many cancer cell lines and impairs tumor growth (Bauer et al., 2005, Hanai et al., 2012, Hatziv

• Loss of expression or functional activity of

  2023-10-17

  

  Loss of expression or functional activity of cell adhesion is intricately related to advanced stages of tumour progression and invasiveness. Martin-Belmonte and Perez-Moreno recently mentioned that the deregulation of adhesion can alter tumourgenesis in the early stage. We have shown for the first t

16604 records 260/1107 page Previous Next First page 上5页 256257258259260 下5页 Last page